New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2013
09:15 EDTSTEMStemCells spinal cord injury trial approved by Health Canada
StemCells announced that Health Canada has authorized the company to expand its Phase I/II clinical trial for chronic spinal cord injury into Canada. The Phase I/II trial, currently underway in Zurich, Switzerland, is designed to evaluate the safety and preliminary efficacy of the company's proprietary HuCNS-SC product candidate, or purified human neural stem cells, as a treatment for chronic spinal cord injury. With this authorization from Health Canada, the company is actively working to open one or more trial sites in Canada and begin screening patients.
News For STEM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2015
08:13 EDTSTEMStemCells completes enrollment in first cohort of Phase II Pathway Study
StemCells announced that it has completed transplanting the six patients comprising the first cohort of its Phase II Pathway Study. The first cohort is an open-label dose escalation arm to determine the cell dose to be used for the second cohort of the study. The second cohort of the study is a single-blind arm in 40 patients that will assess efficacy of the company's proprietary HuCNS-SC platform technology for the treatment of cervical spinal cord injury.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use